Genmab — Share Issue/Capital Change 2016

Nov 9, 2016

Company Announcement

Copenhagen, Denmark; November 9, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN)
will increase its share capital by 101,459 shares as a consequence of the
exercise of employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 2,500 shares at DKK 40.41,
-- 500 shares at DKK 67.50,
-- 5,000 shares at DKK 68.65,
-- 1,625 shares at DKK 79.25,
-- 11,600 shares at DKK 80.55,
-- 10,125 shares at DKK 129.75,
-- 1,500 shares at DKK 210,
-- 4,924 shares at DKK 220.40,
-- 50 shares at DKK 231.50,
-- 5,000 shares at DKK 234,
-- 1,150 shares at DKK 234.75,
-- 250 shares at DKK 246,
-- 6,400 shares at DKK 254,
-- 6,000 shares at DKK 272,
-- 1,350 shares at DKK 329,
-- 1,000 shares at DKK 337.40,
-- 31,034 shares at DKK 352.50,
-- 8,963 shares at DKK 364,
-- 238 shares at DKK 623.50 and
-- 2,250 shares at DKK 636.50.

Proceeds to the company are approximately DKK 25.6 million. The increase
corresponds to approx. 0.2 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2016. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish Business
Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on
Issuers' Disclosure Obligations, it is hereby announced, that the total nominal
value of Genmab A/S' share capital after the capital increase is DKK
60,350,056, which is made up of 60,350,056 shares of a nominal value of DKK 1
each, corresponding to 60,350,056 votes.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. A subcutaneous formulation of
ofatumumab is in development for relapsing multiple sclerosis. Daratumumab is
in clinical development for additional multiple myeloma indications and for
non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical
product pipeline. Genmab's technology base consists of validated and
proprietary next generation antibody technologies - the DuoBody® platform for
generation of bispecific antibodies, and the HexaBody® platform which creates
effector function enhanced antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 51
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark